Crossmark

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-022-06360-3

Published Online: 2022-06-20

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karita, Etienne

Nyombayire, Julien

Ingabire, Rosine

Mazzei, Amelia

Sharkey, Tyronza

Mukamuyango, Jeannine

Allen, Susan

Tichacek, Amanda

Parker, Rachel

Priddy, Frances

Sayinzoga, Felix

Nsanzimana, Sabin

Robinson, Cynthia

Katwere, Michael

Anumendem, Dickson

Leyssen, Maarten

Schaefer, Malinda

Wall, Kristin M.
Funding

Funding for this research was provided by:

Coalition for Epidemic Preparedness Innovations
License Information

Text and Data Mining valid from 2022-06-20

Version of Record valid from 2022-06-20
More Information

Article History

Received: 27 April 2021

Accepted: 26 April 2022

First Online: 20 June 2022

Declarations

:

: This protocol has been approved by the Institutional Review Boards of the Rwanda National Ethics Committee and Emory University. Written, informed consent to participate will be obtained from all participants.

: A model consent form is available upon request.

: The trial principal investigators have no conflicts of interest. Cynthia Robinson, Michael Katwere, Dickson Anumendem, and Maarten Leyssen, are employees of Janssen.

Document is current

Any future updates will be listed below